Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 96 0.00 (0.00%)
As of 09/4/2026
Compare

SPEC vs. NIOX, TSTL, EKF, CREO, and IUG

Should you buy INSPECS Group stock or one of its competitors? INSPECS Group's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does INSPECS Group compare to NIOX Group?

INSPECS Group (LON:SPEC) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

NIOX Group has a net margin of 14.37% compared to INSPECS Group's net margin of -2.67%. NIOX Group's return on equity of 10.14% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
NIOX Group 14.37%10.14%3.95%

NIOX Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.55-£4.11M-£9.40N/A
NIOX Group£48.70M5.81£995.88M£1.6440.99

INSPECS Group has a beta of 1.607, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
NIOX Group Neutral

INSPECS Group presently has a consensus price target of GBX 60, indicating a potential downside of 37.50%. NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 27.94%. Given NIOX Group's higher probable upside, analysts plainly believe NIOX Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NIOX Group beats INSPECS Group on 9 of the 12 factors compared between the two stocks.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Tristel has a beta of 0.346, meaning that its stock price is 65% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market.

22.4% of Tristel shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 19.6% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -2.67%-6.07%0.45%

INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 37.50%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts clearly believe INSPECS Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
INSPECS Group Neutral

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M4.03£6.54M£16.2425.55
INSPECS Group£191.70M0.55-£4.11M-£9.40N/A

Summary

Tristel beats INSPECS Group on 9 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

EKF Diagnostics has a net margin of 4.12% compared to INSPECS Group's net margin of -2.67%. EKF Diagnostics' return on equity of 3.01% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
INSPECS Group -2.67%-6.07%0.45%

EKF Diagnostics has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, indicating that its share price is 61% more volatile than the broader market.

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 37.19%. INSPECS Group has a consensus target price of GBX 60, indicating a potential downside of 37.50%. Given EKF Diagnostics' higher possible upside, research analysts clearly believe EKF Diagnostics is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

EKF Diagnostics has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.12£4.68M£0.4754.28
INSPECS Group£191.70M0.55-£4.11M-£9.40N/A

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 40.2% of EKF Diagnostics shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
INSPECS Group Neutral

Summary

EKF Diagnostics beats INSPECS Group on 10 of the 12 factors compared between the two stocks.

How does INSPECS Group compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.28-£25.04M£1.0012.70
INSPECS Group£191.70M0.55-£4.11M-£9.40N/A

Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.607, indicating that its stock price is 61% more volatile than the broader market.

Creo Medical Group has a net margin of 88.33% compared to INSPECS Group's net margin of -2.67%. Creo Medical Group's return on equity of 9.56% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
INSPECS Group -2.67%-6.07%0.45%

Creo Medical Group currently has a consensus price target of GBX 40, suggesting a potential upside of 214.99%. INSPECS Group has a consensus price target of GBX 60, suggesting a potential downside of 37.50%. Given Creo Medical Group's higher probable upside, research analysts clearly believe Creo Medical Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Creo Medical Group had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for INSPECS Group. Creo Medical Group's average media sentiment score of 0.75 beat INSPECS Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
INSPECS Group Neutral

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 7.0% of Creo Medical Group shares are owned by insiders. Comparatively, 19.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Creo Medical Group beats INSPECS Group on 9 of the 16 factors compared between the two stocks.

How does INSPECS Group compare to Intelligent Ultrasound Group?

INSPECS Group (LON:SPEC) and Intelligent Ultrasound Group (LON:IUG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

INSPECS Group has a beta of 1.607, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Intelligent Ultrasound Group has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.55-£4.11M-£9.40N/A
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

INSPECS Group has a net margin of -2.67% compared to Intelligent Ultrasound Group's net margin of -23.11%. INSPECS Group's return on equity of -6.07% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 37.50%. Given Intelligent Ultrasound Group's higher probable upside, analysts clearly believe Intelligent Ultrasound Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Intelligent Ultrasound Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Intelligent Ultrasound Group Neutral

0.7% of INSPECS Group shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

INSPECS Group beats Intelligent Ultrasound Group on 9 of the 13 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£104.81M£5.66B£7.21B£2.91B
Dividend Yield2.00%1.76%2.54%6.23%
P/E Ratio-10.2125.99273.81366.74
Price / Sales0.5572.98625.3184,203.89
Price / Cash1.6333.4228.9227.89
Price / Book0.966.1011.016.73
Net Income-£4.11M£150.94M£3.49B£5.89B
7 Day Performance3.78%-1.00%1.64%12.16%
1 Month Performance1.32%1.08%4.43%1.56%
1 Year Performance128.03%9.99%24.20%21.58%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
0.4623 of 5 stars		GBX 96
flat		GBX 60
-37.5%		+128.0%£104.81M£191.70MN/A1,673
NIOX
NIOX Group
N/AGBX 68
-0.3%		GBX 86
+26.5%		-8.4%£287.03M£48.70M41.4692
TSTL
Tristel
N/AGBX 419.73
+0.5%		N/A+11.1%£200.71M£49.54M25.85208
EKF
EKF Diagnostics
N/AGBX 25.30
-0.4%		GBX 35
+38.3%		-18.3%£108.82M£51.56M53.83356
CREO
Creo Medical Group
N/AGBX 13.25
+1.9%		GBX 40
+201.9%		+0.4%£63.15M£6M13.25279

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 9/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel